Exhibit 99.1
March 6, 2017

TransEnterix, Inc. Reports Operating Results for the Fourth Quarter and Full Year 2016

RESEARCH TRIANGLE PARK, N.C.—(BUSINESS WIRE)— TransEnterix, Inc. (NYSE MKT:TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced its operating and financial results for the fourth quarter and full year 2016.

Recent Highlights

On February 23, 2017, the Company sold a SenhanceTM Surgical Robotic System to St. Marien-Krankenhaus Siegen, a large multi-specialty hospital, establishing the hospital’s robotic surgical program.

We expanded our Clinical Leadership Program to three sites, which now includes installed systems in France, Italy and the United Kingdom.

On January 5, 2017, the Company received an additional 5 million investment, or approximately $5.2 million, from SOFAR S.p.A.

On December 15, 2016, the Company entered into a common stock purchase agreement, providing the Company with up to $25 million over 36-months from date of execution.

“We are pleased with the significant progress we made during the year in establishing a strong foundation for Senhance commercialization,” said Todd M. Pope, President and Chief Executive Officer of TransEnterix. “We are excited about the opportunity to leverage that foundation to drive growth in Europe and other regions, and look forward to the submission of our Senhance 510(k) and anticipated approval in 2017.”

Financial Highlights

For the three months ended December 31, 2016, the Company reported revenue of $53 thousand, consisting of the recognition of deferred and services revenue associated with existing placements.

For the three months ended December 31, 2016, total operating expenses were $14.4 million, as compared to $13.9 million in the three months ended December 31, 2015.

For the three months ended December 31, 2016, net loss was $14.0 million, or $(0.12) per share, as compared to $13.6 million, or $(0.13) per share, in the three months ended December 31, 2015.

For the full year ended December 31, 2016, the Company reported revenue of $1.5 million, representing the sale of a Senhance system, net of deferred revenue, as well as the recognition of deferred and service revenue associated with existing placements.

For the full year ended December 31, 2016, total operating expenses were $124.1 million, including primarily non-cash charges for goodwill impairment of $61.8 million and restructuring charges of $5.6 million taken in the second quarter of 2016, as compared to $46.4 million in the full year ended December 31, 2015.

For the full year ended December 31, 2016, net loss was $120.0 million, or $1.07 per share, as compared to $46.9 million, or $0.59 per share, in the full year ended December 31, 2015.

The Company had cash, cash equivalents and restricted cash of approximately $34.6 million as of December 31, 2016. The Company expects its existing cash, cash equivalents and restricted cash to fund operations into the fourth quarter of 2017. Pursuant to the disclosure requirements of the NYSE MKT Company Guide Section 610(b), the Company is reporting that its audited consolidated financial statements for the fiscal year ended December 31, 2016, included in the Company’s Annual Report on Form 10-K filed expected to be filed with the Securities and Exchange Commission on or about March 6, 2017, contains an audit opinion from its independent registered public accounting firm that includes an explanatory paragraph related to the Company’s ability to continue as a going concern.

Conference Call
TransEnterix, Inc. will host a conference call on Monday, March 6, 2017 at 4:30 PM ET to discuss its fourth quarter and full year 2016 operating and financial results. To listen to the conference call on your telephone, please dial (888) 724-9516 for domestic callers or (913) 312-0978 for international callers and reference TransEnterix Call approximately ten minutes prior to the start time. To access the live audio webcast or archived recording, use the following link http://ir.transenterix.com/events.cfm. The replay will be available on the Company’s website.

About TransEnterix
TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The Company is focused on the commercialization of the Senhance™ Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The Company also developed the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance Surgical Robotic System has been granted a CE Mark but is not currently available for sale in the United States. For more information, visit the TransEnterix website at www.transenterix.com.

Forward-Looking Statements

This press release includes statements relating to our fourth quarter and full year 2016 results, the Senhance™ Surgical Robotic System and our current regulatory and commercialization plans for this product. These statements and other statements regarding our future plans and goals constitute “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations, including when we will file the 510(k) submission for the Senhance Surgical Robotic System, whether the Senhance 510(k) will be approved by the FDA in 2017, whether our commercialization plans and the development of our pipeline will be successful, and whether existing cash, cash equivalents and restricted cash will fund operations into the fourth quarter of 2017. For a discussion of the risks and uncertainties associated with TransEnterix’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2016, which we expect to file shortly, and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

TransEnterix, Inc.
Consolidated Balance Sheets
(in thousands, except share amounts)

(unaudited)

                         
    December 31, December 31,
    2016 2015
Assets
                       
Current Assets
                       
Cash and cash equivalents
  $ 24,165           $ 38,449
Accounts receivable, net
  621           76
Inventories
  7,883           6,625
Interest receivable
  12           6
Other current assets
  5,335           3,987
 
                       
Total Current Assets
  38,016           49,143
 
                       
Restricted cash
  10,425          
Accounts receivable, net of current portion
  266          
Inventories, net of current portion
            709
Property and equipment, net
  5,772           4,408
Intellectual property, net
  37,090           46,898
In-process research and development
  15,920           16,511
Goodwill
  68,697           130,869
Other long term assets
  63           64
 
                       
Total Assets
  $ 176,249           $ 248,602
 
                       
Liabilities and Stockholders’ Equity
                       
Current Liabilities
                       
Accounts payable
  $ 3,984           $ 4,450
Accrued expenses
  8,206           7,395
Contingent consideration – current portion
  10,502           12,500
Notes payable — current portion, net of debt discount
  7,997           6,727
 
                       
Total Current Liabilities
  30,689           31,072
Long Term Liabilities
                       
Contingent consideration – less current portion
  12,298           11,000
Notes payable — less current portion, net of debt discount
  4,995           12,990
Net deferred tax liabilities
  10,397           16,263
 
                       
Total Liabilities
  58,379           71,325
Commitments and Contingencies
                       
Stockholders’ Equity
                       
Common stock $0.001 par value, 750,000,000 shares authorized at December 31, 2016 and 2015, respectively; 115,781,030 and 100,180,872 shares issued at December 31, 2016 and 2015, respectively; and 115,687,351 and 100,149,453 shares outstanding at December 31, 2016 and 2015, respectively
  115           100
Additional paid-in capital
  426,609           363,280
Accumulated deficit
  (302,844 )           (182,864 )
Treasury stock at cost, 93,679 and 31,419 shares at December 31, 2016 and 2015, respectively
  (241 )           (73 )
Accumulated other comprehensive loss
  (5,769 )           (3,166 )
 
                       
Total Stockholders’ Equity
  117,870           177,277
 
                       
Total Liabilities and Stockholders’ Equity
  $ 176,249           $ 248,602
 
                       

TransEnterix, Inc.
Consolidated Statements of Cash Flows
(in thousands)

(unaudited)

                         
         
    Year Ended Year Ended
    December 31, December 31,
    2016 2015
Operating Activities
                       
Net loss
  $   (119,980 )   $ (46,948 )
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
                       
Depreciation
          1,942   1,248
Amortization of intangible assets
          6,967   2,185
Amortization of debt discount and debt issuance costs
          177   142
Stock-based compensation
          5,033   3,311
Common stock issued for services
          116  
Inventory write-down related to restructuring
          2,565  
Loss on disposal of property
            34
Non-cash restructuring and other charges
          2,556  
Goodwill impairment
          61,784  
Deferred tax benefit
          (5,562 )   (1,024 )
Change in fair value of contingent consideration
          482   (400 )
Changes in operating assets and liabilities, net of effect of acquisition:
                       
Accounts receivable
          (1,041 )   133
Interest receivable
          (6 )   (5 )
Inventories
          (6,647 )   (4,630 )
Other current and long term assets
          (1,528 )   728
Accounts payable
          (356 )   1,096
Accrued expenses
          1,112   5,371
 
               
Net cash and cash equivalents used in operating activities
          (52,386 )   (38,759 )
 
               
Investing Activities
                       
Payment for acquisition of a business
            (25,000 )
Purchase of property and equipment
          (1,361 )   (1,234 )
 
               
Net cash and cash equivalents (used in) provided by investing activities
          (1,361 )   (26,234 )
 
               
Financing Activities
                       
Payment of debt
          (6,902 )  
Payment of contingent consideration
          (1,182 )  
Proceeds from issuance of common stock, net of issuance costs
          58,029   58,331
Proceeds from issuance of debt, net of debt discount
            9,887
Taxes paid related to net share settlement of vesting of restricted
          (168 )   (73 )
stock units
                       
Proceeds from exercise of stock options and warrants
          166   259
 
               
Net cash and cash equivalents provided by financing activities
          49,943   68,404
 
               
Effect of exchange rate changes on cash and cash equivalents
          (55 )   22
 
               
Net (decrease) increase in cash, cash equivalents and restricted cash
          (3,859 )   3,433
Cash, cash equivalents and restricted cash, beginning of period
          38,449   35,016
 
               
Cash, cash equivalents and restricted cash, end of period
          $ 34,590   $ 38,449
 
           
Supplemental Disclosure for Cash Flow Information
                       
Interest paid
          $ 1,289   $ 973
Supplemental Schedule of Noncash Investing Activities
                       
Transfer of inventory to property and equipment
          $ 3,198  
Issuance of common stock warrants
            $ 97
Contingent consideration related to acquisition
            $ 23,900
Issuance of common stock related to acquisition
            $ 43,677

TransEnterix, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share amounts)

(unaudited)

                                                 
        Three Months Ended       Year Ended
        December 31,       December 31,
        2016       2015       2016       2015
Revenue
      $ 53         $         $ 1,519         $  
Cost of revenue
        38                     1,069            
 
                                               
Gross profit
        15                     450            
 
                                               
Operating Expenses
                                               
Research and development
        7,513           8,558           29,273           29,669  
Sales and marketing
        3,588           1,694           9,151           2,855  
General and administrative
        2,886           2,224           10,813           7,831  
Amortization of intangible assets
        1,655           1,596           6,967           2,185  
Change in fair value of contingent
consideration
 
 
 
(1,218)
 
 
 
(400)
 
 
 
482
 
 
 
(400)
Inventory write-down related to
restructuring
 
 
 
 
 
 
 
 
 
2,565
 
 
 
Restructuring and other charges
        (21 )                   3,064            
Goodwill impairment
                            61,784            
Acquisition related costs
                  228                     4,231  
Total Operating Expenses
        14,403           13,900           124,099           46,371  
 
                                               
Operating Loss
        (14,388 )         (13,900 )         (123,649 )         (46,371 )
 
                                               
Other Expense
                                               
Interest expense, net
        (390 )         (604 )         (1,889           (1,601 )
Other (expense) income
        (30 )                   35            
 
                                               
Total Other Expense, net
        (420 )         (604 )         (1,854 )         (1,601 )
 
                                               
Loss before income taxes
      $ (14,808         $ (14,504 )       $ (125,503 )       $ (47,972 )
Income tax benefit
        816           925           5,523           1,024  
Net loss
      $ (13,992 )       $ (13,579 )       $ (119,980 )       $ (46,948 )
 
                                               
Other comprehensive gain (loss)
                                               
Foreign currency translation gain (loss)
        (4,802 )         (2,737 )         (2,603 )         (3,166 )
 
                                               
Comprehensive loss
      $ (18,794 )       $ (16,316 )       $ (122,583 )       $ (50,114 )
 
                                               
Net loss per share — basic and diluted
      $ (0.12 )       $ (0.13 )       $ (1.07 )       $ (0.59 )
Weighted average common shares
outstanding -
   basic and diluted
 

 
 

115,151
 

 
 

100,145
 

 
 

112,185
 

 
 

79,628


The following information was filed by Transenterix Inc. (TRXC) on Wednesday, March 8, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Transenterix Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Transenterix Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account